Roche Pushes Respiratory Agenda In Early Inflammatory Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Four novel drugs are in the clinic for asthma and chronic obstructive pulmonary disease.
You may also be interested in...
Roche's Lebrikizumab Shows Potential For Biomarker Targeting In Asthma
Phase II data published in NEJM show that biomarker-assisted therapies could be valuable in targeting the variabilities of the disease.
Roche's Lebrikizumab Shows Potential For Biomarker Targeting In Asthma
Phase II data published in NEJM show that biomarker-assisted therapies could be valuable in targeting the variabilities of the disease.
Roche’s Actemra Gets Advisory Committee Review
FDA’s Arthritis Drugs Advisory Committee evaluates the interleukin-6 receptor inhibitor for rheumatoid arthritis July 29.